TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
Brief Summary: The primary efficacy objective of this study is to compare the coefficient of fat absorption (CFA) following oral administration of Aptalis Pharma's (formerly Eurand Pharmaceuticals) pancreatic enzyme product (PEP) capsules and placebo in participants with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI).


Options:
A: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: porcine (pig) PERT; Type: ACTIVE_COMPARATOR; Interventions: Drug: porcine (pig) PERT | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: porcine (pig) PERT; Assigned to Arm(s): porcine (pig) PERT
D: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
Brief Summary: The primary efficacy objective of this study is to compare the coefficient of fat absorption (CFA) following oral administration of Aptalis Pharma's (formerly Eurand Pharmaceuticals) pancreatic enzyme product (PEP) capsules and placebo in participants with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI).


Options:
A: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
B: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Stem Cell Transplantation for Crohn's Disease: ASTIC
Brief Summary: Transplant study for patients with relapsing Crohn's disease demonstrating clear intolerance or toxicity to conventional treatment.

The purpose of this study is to determine whether there is a potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice.


Options:
A: Arm Label: Transplant Arm; Type: EXPERIMENTAL; Interventions: Procedure: Autologous haematopoietic stem cell transplant | Arm Label: Delayed Transplant; Type: EXPERIMENTAL; Interventions: Procedure: Autologous haematopoietic stem cell transplant | Intervention Type: PROCEDURE; Name: Autologous haematopoietic stem cell transplant; Assigned to Arm(s): Delayed Transplant, Transplant Arm
B: Arm Label: Hematopoietic Stem Cell Transplant Regimen 2; Type: EXPERIMENTAL; Interventions: Biological: Hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: Hematopoietic stem cell transplantation; Assigned to Arm(s): Hematopoietic Stem Cell Transplant Regimen 2
C: Arm Label: Mesenchymal Stem Cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal Stem Cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Mesenchymal Stem Cells; Assigned to Arm(s): Mesenchymal Stem Cells | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection. | Arm Label: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. | Arm Label: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. | Arm Label: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. | Intervention Type: PROCEDURE; Name: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.; Assigned to Arm(s): Control group | Intervention Type: PROCEDURE; Name: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder
Brief Summary: The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots). Risperidone has been used successfully to treat schizophrenia and schizoaffective disorder.


Options:
A: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: atypical antipsychotics:oral vs. long-acting route; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Psychoeducation; Assigned to Arm(s): N/A
C: Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670
D: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder
Brief Summary: The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots). Risperidone has been used successfully to treat schizophrenia and schizoaffective disorder.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone Palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Paliperidone Palmitate; Assigned to Arm(s): 001
B: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot
C: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A
D: Arm Label: Bifeprunox; Type: EXPERIMENTAL; Interventions: Drug: Bifeprunox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Bifeprunox; Assigned to Arm(s): Bifeprunox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder
Brief Summary: The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots). Risperidone has been used successfully to treat schizophrenia and schizoaffective disorder.


Options:
A: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A
B: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol
C: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: main antipsychotic medication and placebo | Intervention Type: DRUG; Name: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: main antipsychotic medication and placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies to Help Adult ED Patients Quit Smoking
Brief Summary: The purpose of this study is to determine whether a brief, focused intervention in the hospital emergency department is effective in helping adults quit smoking.


Options:
A: Intervention Type: DRUG; Name: transdermal nicotine patches; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Motivational interview; Assigned to Arm(s): N/A
B: Arm Label: High intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: High intensity disease management, Drug: Bupropion | Arm Label: Low intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Low intensity disease management, Drug: Bupropion | Arm Label: Comparison group; Type: OTHER; Interventions: Behavioral: Comparison group, Drug: Bupropion | Intervention Type: BEHAVIORAL; Name: High intensity disease management; Assigned to Arm(s): High intensity disease management | Intervention Type: BEHAVIORAL; Name: Low intensity disease management; Assigned to Arm(s): Low intensity disease management | Intervention Type: BEHAVIORAL; Name: Comparison group; Assigned to Arm(s): Comparison group | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Comparison group, High intensity disease management, Low intensity disease management
C: Arm Label: PRO+NRT+TC; Type: EXPERIMENTAL; Interventions: Other: proactive outreach (PRO), Other: telephone counseling (TC), Other: Nicotine replacement therapy (NRT) | Arm Label: Usual Care (UC); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care (UC) | Intervention Type: OTHER; Name: proactive outreach (PRO); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: telephone counseling (TC); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Nicotine replacement therapy (NRT); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Usual care (UC); Assigned to Arm(s): Usual Care (UC)
D: Arm Label: Standard Care; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care | Arm Label: Motivational Enhancement; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement; Assigned to Arm(s): Motivational Enhancement

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Therapy for Nicotine Dependence
Brief Summary: The goal of this behavioral research study is to create and study a Mindfulness-Based Addiction Treatment (MBAT) for nicotine dependence. Mindfulness is a method to help focus attention on being in the "here and now." It can be learned through training in how to control one's attention. It is usually taught through meditation. The overarching goals of the study are to evaluate the efficacy of MBAT for nicotine dependence and the mechanisms and effects posited to mediate MBAT's impact on abstinence.


Options:
A: Arm Label: Face-to-face group-based mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face group-based mindfulness | Arm Label: Internet-based mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based mindfulness | Arm Label: Waiting-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face group-based mindfulness; Assigned to Arm(s): Face-to-face group-based mindfulness | Intervention Type: BEHAVIORAL; Name: Internet-based mindfulness; Assigned to Arm(s): Internet-based mindfulness
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: yoga, Behavioral: cognitive therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive therapy, Behavioral: wellness | Intervention Type: BEHAVIORAL; Name: yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: cognitive therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: wellness; Assigned to Arm(s): 2
C: Arm Label: Mindfulness-Based Treatment Group (MBAT); Type: EXPERIMENTAL; Interventions: Behavioral: MBAT Group Therapy, Drug: Nicotine | Arm Label: Standard Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Group Therapy | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Individual Therapy | Intervention Type: BEHAVIORAL; Name: MBAT Group Therapy; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT) | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT), Standard Care Group, Usual Care Group | Intervention Type: BEHAVIORAL; Name: Group Therapy; Assigned to Arm(s): Standard Care Group | Intervention Type: BEHAVIORAL; Name: Individual Therapy; Assigned to Arm(s): Usual Care Group
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-delivered Intervention (SmartQuit) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: : Smartphone-delivered Intervention (Standard of care app) | Intervention Type: BEHAVIORAL; Name: Smartphone-delivered Intervention (SmartQuit); Assigned to Arm(s): Experimental | Intervention Type: BEHAVIORAL; Name: : Smartphone-delivered Intervention (Standard of care app); Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Therapy for Nicotine Dependence
Brief Summary: The goal of this behavioral research study is to create and study a Mindfulness-Based Addiction Treatment (MBAT) for nicotine dependence. Mindfulness is a method to help focus attention on being in the "here and now." It can be learned through training in how to control one's attention. It is usually taught through meditation. The overarching goals of the study are to evaluate the efficacy of MBAT for nicotine dependence and the mechanisms and effects posited to mediate MBAT's impact on abstinence.


Options:
A: Arm Label: Mindfulness-Based Treatment Group (MBAT); Type: EXPERIMENTAL; Interventions: Behavioral: MBAT Group Therapy, Drug: Nicotine | Arm Label: Standard Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Group Therapy | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Individual Therapy | Intervention Type: BEHAVIORAL; Name: MBAT Group Therapy; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT) | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT), Standard Care Group, Usual Care Group | Intervention Type: BEHAVIORAL; Name: Group Therapy; Assigned to Arm(s): Standard Care Group | Intervention Type: BEHAVIORAL; Name: Individual Therapy; Assigned to Arm(s): Usual Care Group
B: Arm Label: 1; Type: OTHER; Interventions: Other: Counselor-Initiated Tobacco Quit Line | Arm Label: 2; Type: OTHER; Interventions: Other: Self-Paced Tobacco Quit Line | Intervention Type: OTHER; Name: Counselor-Initiated Tobacco Quit Line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Self-Paced Tobacco Quit Line; Assigned to Arm(s): 2
C: Arm Label: Enhanced Care; Type: EXPERIMENTAL; Interventions: Drug: Nicorette Gum, Drug: Nicoderm CQ, Other: Smoking Quitline Referral, Behavioral: Behavioral Smoking Cessation Counseling | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicorette Gum, Drug: Nicoderm CQ, Other: Smoking Quitline Referral | Intervention Type: DRUG; Name: Nicorette Gum; Assigned to Arm(s): Enhanced Care, Standard Care | Intervention Type: DRUG; Name: Nicoderm CQ; Assigned to Arm(s): Enhanced Care, Standard Care | Intervention Type: OTHER; Name: Smoking Quitline Referral; Assigned to Arm(s): Enhanced Care, Standard Care | Intervention Type: BEHAVIORAL; Name: Behavioral Smoking Cessation Counseling; Assigned to Arm(s): Enhanced Care
D: Arm Label: Intensive behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Positively Smoke Free | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Positively Smoke Free; Assigned to Arm(s): Intensive behavioral intervention | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care

Answer: A